TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Rhythm Biosciences Ltd. ( (AU:RHY) ).
Rhythm Biosciences Ltd has successfully transitioned its geneType™ Laboratory to the ISO 15189:2022 standard, securing updated accreditation. This achievement allows Rhythm to continue delivering its geneType™ risk assessment service and positions the company to commercialize its ColoSTAT® test as an in-house IVD, pending further assessment. The transition will also help optimize operational costs by eliminating the need for ISO13485 status. This strategic move strengthens Rhythm’s laboratory systems and supports a unified commercial strategy for its products, enhancing market access and operational efficiency.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple and affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden through early diagnosis. Rhythm collaborates with global partners to commercialize and distribute its solutions, including the ColoSTAT® test for colorectal cancer and the geneType™ platform for genetic risk assessment across multiple diseases.
Average Trading Volume: 348,097
Technical Sentiment Signal: Buy
Current Market Cap: A$28.34M
For a thorough assessment of RHY stock, go to TipRanks’ Stock Analysis page.